ABBV - AbbVie Inc.
NYSE
->
Healthcare
->
Drug Manufacturers—General
North Chicago,
United States
Type: Equity
ABBV price evolution
ABBV
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $13130 | $18067 | $12814 | |
| Short term investments | $27 | $2 | $2 | |
| Net receivables | $11472 | $11724 | $11949 | $11155 |
| Inventory | $4450 | $4218 | $4245 | $4099 |
| Total current assets | $27785 | $33816 | $38871 | $33002 |
| Long term investments | $272 | $305 | $304 | |
| Property, plant & equipment | $5141 | $5023 | $4980 | $4989 |
| Goodwill & intangible assets | $93629 | $95651 | $87903 | |
| Total noncurrent assets | $108121 | $110003 | $101709 | |
| Total investments | $299 | $307 | $306 | |
| Total assets | $143422 | $141937 | $148874 | $134711 |
| Current liabilities | ||||
| Accounts payable | $30492 | $29329 | $31326 | $30650 |
| Deferred revenue | ||||
| Short long term debt | $12586 | $10196 | $7191 | |
| Total current liabilities | $43062 | $41915 | $41522 | $37841 |
| Long term debt | $58509 | $58048 | $63805 | $52194 |
| Total noncurrent liabilities | $93201 | $99305 | $86473 | |
| Total debt | $70634 | $74001 | $59385 | |
| Total liabilities | $137390 | $135116 | $140827 | $124314 |
| Shareholders' equity | ||||
| Retained earnings | -$4964 | -$3768 | -$2384 | -$1000 |
| Other shareholder equity | -$2334 | -$2513 | -$2454 | -$2305 |
| Total shareholder equity | $6778 | $8007 | $10360 | |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $12814 | $9201 | $9746 | $8449 |
| Short term investments | $2 | $28 | $84 | $30 |
| Net receivables | $11155 | $11254 | $9977 | $8822 |
| Inventory | $4099 | $3579 | $3128 | $3310 |
| Total current assets | $33002 | $28463 | $27928 | $24173 |
| Long term investments | $304 | $241 | $277 | $293 |
| Property, plant & equipment | $4989 | $5672 | $5110 | $5248 |
| Goodwill & intangible assets | $87903 | $99595 | $108330 | $116000 |
| Total noncurrent assets | $101709 | $110342 | $118601 | $126392 |
| Total investments | $306 | $269 | $361 | $323 |
| Total assets | $134711 | $138805 | $146529 | $150565 |
| Current liabilities | ||||
| Accounts payable | $30650 | $8999 | $22699 | $20159 |
| Deferred revenue | ||||
| Short long term debt | $7191 | $4136 | $12495 | $8502 |
| Total current liabilities | $37841 | $29538 | $35194 | $28661 |
| Long term debt | $52194 | $59135 | $64189 | $77554 |
| Total noncurrent liabilities | $86473 | $91980 | $95899 | $108807 |
| Total debt | $59385 | $63271 | $76684 | $86056 |
| Total liabilities | $124314 | $121551 | $131093 | $137468 |
| Shareholders' equity | ||||
| Retained earnings | -$1000 | $4784 | $3127 | $1055 |
| Other shareholder equity | -$2305 | -$2199 | -$2899 | -$3117 |
| Total shareholder equity | $10360 | $17254 | $15408 | $13076 |
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | ||||
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | ||||
| Income (for common shares) | ||||
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Jan 2022 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $54318 | $58054 | $45804 | |
| Cost of revenue | $20415 | $17414 | $15387 | |
| Gross Profit | $33903 | $40640 | $30417 | |
| Operating activities | ||||
| Research & development | $7675 | $6510 | $6557 | |
| Selling, general & administrative | $12872 | $15260 | $11299 | |
| Total operating expenses | $21146 | $22523 | $19054 | |
| Operating income | $12757 | $18117 | $11363 | |
| Income from continuing operations | ||||
| EBIT | $7924 | $15512 | $5672 | |
| Income tax expense | $1377 | $1632 | -$1224 | |
| Interest expense | $1684 | $2044 | $2280 | |
| Net income | ||||
| Net income | $4863 | $11836 | $4616 | |
| Income (for common shares) | $4863 | $11836 | $4616 | |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | $1370 | $1369 | $822 | |
| Operating activities | ||||
| Depreciation | $2131 | $2074 | $2076 | |
| Business acquisitions & disposals | -$843 | -$9389 | -$553 | |
| Stock-based compensation | $218 | $348 | $125 | |
| Total cash flows from operations | $2271 | $4040 | $4753 | |
| Investing activities | ||||
| Capital expenditures | -$241 | -$193 | -$205 | |
| Investments | -$13 | -$20 | ||
| Total cash flows from investing | -$18946 | -$1102 | -$9588 | -$800 |
| Financing activities | ||||
| Dividends paid | -$8273 | -$2750 | -$2772 | -$2626 |
| Sale and purchase of stock | $1 | -$1197 | $28 | |
| Net borrowings | -$3348 | $14764 | -$1832 | |
| Total cash flows from financing | $1650 | -$6097 | $10819 | -$4449 |
| Effect of exchange rate | -$19 | -$9 | -$18 | $23 |
| Change in cash and equivalents | -$5557 | -$4937 | $5253 | -$473 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $4863 | $11836 | $11542 | $4616 |
| Operating activities | ||||
| Depreciation | $8698 | $8467 | $8521 | $6471 |
| Business acquisitions & disposals | -$1223 | -$794 | -$1902 | -$39610 |
| Stock-based compensation | $747 | $671 | $692 | $753 |
| Total cash flows from operations | $22839 | $24943 | $22777 | $17588 |
| Investing activities | ||||
| Capital expenditures | -$777 | -$695 | -$787 | -$798 |
| Investments | -$22 | $92 | -$21 | $1464 |
| Total cash flows from investing | -$2009 | -$623 | -$2344 | -$37557 |
| Financing activities | ||||
| Dividends paid | -$10539 | -$10043 | -$9261 | -$7716 |
| Sale and purchase of stock | -$1792 | -$1225 | -$690 | -$769 |
| Net borrowings | -$4187 | -$12433 | -$8414 | -$2703 |
| Total cash flows from financing | -$17222 | -$24803 | -$19039 | -$11501 |
| Effect of exchange rate | $5 | -$62 | -$97 | -$5 |
| Change in cash and equivalents | $3613 | -$545 | $1297 | -$31475 |
News
Fundamentals
| Market cap | $307.83B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 1.77B |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 12.00 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 0.65 |
| Quick ratio | 0.54 |